Thomas Delea, MS, Policy Analysis Inc. (PAI), Brookline, MA, United States; Charles Makin, MS, Outcomes Reseach Center, Humana Inc., Louisville, KY, United States; Jane Chang, MPH, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, United States; J. Mark Jackson, MD, University of Louisville, Department of Internal Medicine, Division of Dermatology, Louisville, KY, United StatesLe texte complet de cet article est disponible en PDF.
Mr. Delea is a Senior Research Consultant at PAI, an independent contract research organization that has received research funding for this and other projects from Novartis. Mr. Makin is a Pharmacoeconomics and Outcomes Research Fellow at the Humana Outcomes Research Center, which received consulting fees and data acquisition fees for this project from PAI on behalf of Novartis. Ms. Chang is a Health Economics and Outcomes Research Fellow at Novartis. Dr. Jackson has received research, honoraria, and consulting support from Novartis.
100% sponsored by Novartis Pharmaceuticals.